Description
Minwin D-Tab
Minwin D-Tab, as supplied here, is described as an oral fixed-dose combination of minoxidil and dutasteride. The two ingredients belong to different medicine classes and act through complementary pathways that are used in the medical management of pattern hair loss in some settings. Because this is a combination product, its safety profile reflects the known effects of both active ingredients.
Active Ingredient and Medicine Class
Minoxidil is an antihypertensive peripheral vasodilator. Dutasteride is a 5-alpha-reductase inhibitor. In hair-loss treatment, minoxidil is used for its hair-growth promoting effect, while dutasteride reduces formation of dihydrotestosterone, a hormone involved in androgenetic alopecia.
Established Medical Uses
The supplied description presents this medicine as a systemic treatment for androgenetic alopecia, also called pattern hair loss. Scientifically, oral minoxidil and oral dutasteride have both been studied for this condition, but their original regulatory approvals are for other indications. Minoxidil tablets are officially indicated for severe hypertension that is not adequately controlled with other medicines, while dutasteride is officially indicated for benign prostatic hyperplasia in men with an enlarged prostate.
How It Works
Minoxidil relaxes blood vessels and can increase blood flow to tissues. In hair follicles, it is thought to support the growth phase of the hair cycle and may increase hair shaft diameter and density. Dutasteride blocks both type 1 and type 2 5-alpha-reductase enzymes, lowering dihydrotestosterone levels. Since dihydrotestosterone contributes to follicular miniaturization in androgenetic alopecia, reducing it may help slow further hair thinning.
Important Safety Information
This combination contains two medicines with important safety considerations. Oral minoxidil has well-recognized cardiovascular warnings, including fluid retention, rapid heartbeat, worsening angina, and rare but serious pericardial effusion that may progress to tamponade. Minoxidil is contraindicated in pheochromocytoma and in people with hypersensitivity to the product components.
Dutasteride is contraindicated in pregnancy because it may cause harm to a male fetus. It should be handled with particular caution in people who are pregnant or may become pregnant. Dutasteride may also affect prostate-specific antigen interpretation and has important interaction potential with medicines that inhibit CYP3A4 and CYP3A5. Because this is a combination product, prescribers typically consider cardiovascular history, pregnancy-related risk, and potential drug interactions before use.
Possible Side Effects
Reported adverse effects of oral minoxidil include edema, palpitations, tachycardia, headache, and other cardiovascular effects. More serious reactions can include pericardial effusion and worsening heart-related symptoms. Dutasteride is associated with sexual adverse effects such as reduced libido or ejaculation changes, as well as breast tenderness or enlargement in some patients. Postmarketing reports also include hypersensitivity reactions, depressed mood, and rare serious skin reactions.
Scientific Evidence
Human studies suggest that low-dose oral minoxidil can improve hair growth in androgenetic alopecia, and comparative analyses have assessed oral minoxidil alongside dutasteride and finasteride. A recent study reported clinical improvement with low-dose oral minoxidil, including in combination regimens, while broader reviews describe dutasteride as a potent antiandrogen option for male pattern hair loss. These findings support biological plausibility and clinical use in some settings, but they do not establish that every fixed-dose combination product has the same benefit-risk profile.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, product labeling, or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / U.S. prescribing information Minoxidil Tablets, USP
- DailyMed / U.S. prescribing information Dutasteride Capsules
- Ambika Nohria et al. Treatment of androgenetic alopecia with low-dose oral minoxidil monotherapy compared with combination therapy with dutasteride or finasteride. Journal of the American Academy of Dermatology, 2025. View scientific article
- M Larios-Cárdenas et al. Comparative efficacy of oral dutasteride and low-, medium-, and high-dose oral minoxidil: a six-month prospective trichoscopic and clinical study. Frontiers in Medicine, 2026. View scientific article
